P2RY12 and atrial fibrillation: More recently, the ENTRUST-AF PCI trial was reported, in which 1506 patients with AF and PCI for stable CAD or ACS were randomized to dual therapy with edoxaban plus P2Y12 inhibitor or triple therapy with VKA and DAPT [23].